POAI — Predictive Oncology Balance Sheet
0.000.00%
- $49.22m
- $48.98m
- $1.62m
Annual balance sheet for Predictive Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.678 | 28.2 | 22.1 | 8.73 | 0.735 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.257 | 0.354 | 0.331 | 0.334 | 0.746 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1.51 | 29.5 | 23.4 | 10.1 | 2.23 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.22 | 3.33 | 2.05 | 3.96 | 2.43 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 13.1 | 43.8 | 25.7 | 14.4 | 4.97 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 9.34 | 3.24 | 3.88 | 3.95 | 3.59 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 10.4 | 3.51 | 3.97 | 6.15 | 5.18 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 2.64 | 40.3 | 21.8 | 8.27 | -0.203 |
| Total Liabilities & Shareholders' Equity | 13.1 | 43.8 | 25.7 | 14.4 | 4.97 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |